NOTICE: Archived content. Evaluate Ltd acquired BioScience Advisors and its properties in May 2021. The contents of this website belong to Evaluate.
Evolving Deal Terms
If change is the only constant in biopharma alliances, what have we learned from the past?
Compulsory License Provisions in Biopharma Alliances
Evolving Deal Terms
“Who’s on First?” Biopharma Licenses from the Seller’s Perspective
Evolving Deal Terms
Contingent Value Rights Waiting for the Dough
Evolving Deal Terms
You Had Me at “Hello” The Remarkable Growth of Upfront Payments in Biopharma Alliances
Evolving Deal Terms
Biopharma Milestone Payments Negotiating an Equitable Value Allocation
Evolving Deal Terms
Recent Trends & How Far You Can Go
Evolving Deal Terms
Sharing the Wealth Recent Trends in Biopharma Sublicensing
Evolving Deal Terms
Effective Royalty Rates in Biopharma Alliances What They Are and Why Use Them in Negotiations
Evolving Deal Terms
Top Pharma Vs. Major Biotech Who is Biopharma’s Favorite Alliance Partner?
Evolving Deal Terms
Co-Promotion in Biopharma Agreements Success is in the Details
Evolving Deal Terms
Re‐emergence of Platform Technologies Gonna Party Like It’s 1999
Evolving Deal Terms